{
    "rows": [
        {
            "Company": "Nanjing Legend Biotechnology Co.",
            "GenericDrug": "NULL",
            "OtherDrug": "CD19/CD22 CAR-T",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19/CD22",
            "Disease": "B-cell Lymphoma"
        },
        {
            "Company": "Tmunity Therapeutics",
            "GenericDrug": "NULL",
            "OtherDrug": "CART-PSMA-TGFßRDN cells",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "PSMA",
            "Disease": "Castrate Resistant Prostate Cancer"
        },
        {
            "Company": "Pregene",
            "GenericDrug": "NULL",
            "OtherDrug": "HenanCH CAR 2-2",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NS",
            "Target": "NULL",
            "Disease": "Relapsed/Refractory Myeloma"
        },
        {
            "Company": "Shanghai Bioray Laboratory",
            "GenericDrug": "NULL",
            "OtherDrug": "CD19 CART",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Acute Leukemia"
        },
        {
            "Company": "Shanghai GeneChem",
            "GenericDrug": "NULL",
            "OtherDrug": "TAI-Meso CAR-T Cells",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "Mesothelin",
            "Disease": "Pancreatic Cancer"
        },
        {
            "Company": "Wuhan Bio-Raid",
            "GenericDrug": "NULL",
            "OtherDrug": "Anti-CD22 CAR-T cell therapy",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD22",
            "Disease": "Acute Lymphoblastic Leukemia"
        },
        {
            "Company": "Cellectis",
            "GenericDrug": "NULL",
            "OtherDrug": "C-119",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Acute Lymphocytic Leukemia"
        },
        {
            "Company": "Cellectis",
            "GenericDrug": "NULL",
            "OtherDrug": "C-119",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Acute Lymphocytic Leukemia"
        },
        {
            "Company": "Juventas Cell Therapy",
            "GenericDrug": "NULL",
            "OtherDrug": "CNCT19 (CD19 CAR-T)",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Acute Lymphocytic Leukemia"
        },
        {
            "Company": "JW Therapeutics",
            "GenericDrug": "NULL",
            "OtherDrug": " JWCAR029",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "Non Hodgkin Lymphoma"
        },
        {
            "Company": "PersonGen Biomedicine (Suzhou) Co.",
            "GenericDrug": "NULL",
            "OtherDrug": " PCAR-019",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": " I/II",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "Acute Lymphocytic Leukemia"
        },
        {
            "Company": "Juno Therapeutics (Part of Bristol-Myers Squibb)",
            "GenericDrug": "NULL",
            "OtherDrug": "JCAR-024",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "ROR1",
            "Disease": "Chronic Lymphocytic Leukemia"
        },
        {
            "Company": "Juno Therapeutics (Part of Bristol-Myers Squibb)",
            "GenericDrug": "Orvacabtagene Autoleucel",
            "OtherDrug": "BCMA targeting CAR T cell therapy",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Nanjing Bioheng Biotech",
            "GenericDrug": "NULL",
            "OtherDrug": "CTA-101",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Diffuse Large B-cell Lymphoma"
        },
        {
            "Company": "Pregene",
            "GenericDrug": "NULL",
            "OtherDrug": "CD19 CAR-T",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "B-cell Acute Lymphocytic Leukemia"
        },
        {
            "Company": "Mustang Bio (Part of Fortress Biotech)",
            "GenericDrug": "NULL",
            "OtherDrug": "HER2 chimaeric antigen receptor therapy",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "HER-2",
            "Disease": "Glioblastoma"
        },
        {
            "Company": "iCarTAB BioMed",
            "GenericDrug": "NULL",
            "OtherDrug": "CD19 CAR-T",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Chronic B-Cell Lymphocytic Leukemia"
        },
        {
            "Company": "Helix BioPharma",
            "GenericDrug": "NULL",
            "OtherDrug": "CD19 CAR-T Cell Therapy",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Miltenyi Biotec",
            "GenericDrug": "NULL",
            "OtherDrug": "Anti-CD20/19 CAR T cells",
            "Origin": "Germany ",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD20 and CD19",
            "Disease": "B-Cell Non-Hodgkin's Lymphoma"
        },
        {
            "Company": "GAIA Science",
            "GenericDrug": "NULL",
            "OtherDrug": "CD19 CAR-T Cell Therapy",
            "Origin": "Malaysia",
            "Partner": "NULL",
            "Phase": "II/III",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "B Acute Lymphoblastic Leukaemia"
        },
        {
            "Company": "Autolus Limited",
            "GenericDrug": "NULL",
            "OtherDrug": "1RG-CART",
            "Origin": "UK",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "GD2",
            "Disease": "Neuroblastoma"
        },
        {
            "Company": "Precision Biosciences",
            "GenericDrug": "NULL",
            "OtherDrug": "Allogeneic Anti-CD20 CAR T cells",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NS",
            "Target": "CD20",
            "Disease": "Leukemia, Chronic LymphocyticLymphoma, Non-Hodgkin's"
        },
        {
            "Company": "Shanghai Bioray Laboratory",
            "GenericDrug": "NULL",
            "OtherDrug": "PSMA-CART cells",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NS",
            "Target": "Folate hydrolase 1",
            "Disease": "Castrate-Resistant Prostate Cancer"
        },
        {
            "Company": "Shanghai GeneChem",
            "GenericDrug": "NULL",
            "OtherDrug": "MG-7 CAR-T Cells",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "MG-7",
            "Disease": "Liver Metastases"
        },
        {
            "Company": "Immune Cell Therapy",
            "GenericDrug": "NULL",
            "OtherDrug": "ICAR30 CAR-T Cells",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD30",
            "Disease": "NULL"
        },
        {
            "Company": "Eureka Therapeutics",
            "GenericDrug": "NULL",
            "OtherDrug": "Anti-AFP CAR-T",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "HLA-A02/AFP complex",
            "Disease": "NULL"
        },
        {
            "Company": "Servier",
            "GenericDrug": "NULL",
            "OtherDrug": "ALLO-501",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Follicular Lymphoma"
        },
        {
            "Company": "Heibei Sen Lang Biotechnology",
            "GenericDrug": "NULL",
            "OtherDrug": "CD-123 CAR-T",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD33",
            "Disease": "Acute Myelocytic Leukemia"
        },
        {
            "Company": "Juventas Cell Therapy",
            "GenericDrug": "NULL",
            "OtherDrug": "CNCT19 (CD19 CAR-T)",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Acute Lymphocytic Leukemia"
        },
        {
            "Company": "Kite Pharma (Now Gilead Sciences)",
            "GenericDrug": "Axicabtagene ciloleucel ",
            "OtherDrug": "CD19 CAR-T Therapy",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "B-cell Lymphoma"
        },
        {
            "Company": "CARsgen",
            "GenericDrug": "NULL",
            "OtherDrug": "CAR-CLD18",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "NULL"
        },
        {
            "Company": "Legend Biotech",
            "GenericDrug": "NULL",
            "OtherDrug": "JNJ-4528",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Juno Therapeutics (Part of Bristol-Myers Squibb)",
            "GenericDrug": "Lisocabtagene Maraleucel",
            "OtherDrug": "CD19-Specific CAR-T Cell Therapy",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Diffuse Large B-cell Lymphoma"
        },
        {
            "Company": "Juno Therapeutics (Part of Bristol-Myers Squibb)",
            "GenericDrug": "NULL",
            "OtherDrug": "CAR Modified T-Cells",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "NULL"
        },
        {
            "Company": "iCarTAB BioMed",
            "GenericDrug": "NULL",
            "OtherDrug": " CAR-T cell therapy",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "T cell malignancy"
        },
        {
            "Company": "Gracell Biotechnologies",
            "GenericDrug": "NULL",
            "OtherDrug": "CD19 CAR-T Cell Therapy",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "B-cell Acute Lymphoblastic Leukemia"
        },
        {
            "Company": "Gracell Biotechnologies",
            "GenericDrug": "NULL",
            "OtherDrug": "CD19 CAR-T Cell Therapy",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "IV",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Acute Lymphocytic Leukemia"
        },
        {
            "Company": "Sorrento Therapeutics",
            "GenericDrug": "NULL",
            "OtherDrug": " CAR2 Anti-CEA CAR-T cells",
            "Origin": "U.S.",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NS",
            "Target": "CEACAM5",
            "Disease": "Metastatic Pancreatic Carcinoma"
        },
        {
            "Company": "Autolus Limited",
            "GenericDrug": "NULL",
            "OtherDrug": "AUTO2",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Autolus Limited",
            "GenericDrug": "NULL",
            "OtherDrug": "AUTO4",
            "Origin": "UK",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "TRBC1",
            "Disease": "T cell non-Hodgkin Lymphoma"
        },
        {
            "Company": "Pinze Lifetechnology Co.",
            "GenericDrug": "NULL",
            "OtherDrug": " PZ01",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "B-cell Acute Lymphoblastic Leukemia"
        },
        {
            "Company": "PersonGen Biomedicine (Suzhou) Co.",
            "GenericDrug": "NULL",
            "OtherDrug": " PCAR-019",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": " I/II",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "Acute Lymphocytic Leukemia"
        },
        {
            "Company": "Cartesian Therapeutics",
            "GenericDrug": "NULL",
            "OtherDrug": "Descartes-08",
            "Origin": "United States",
            "Partner": "NULL",
            "Phase": "Ib/IIa",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "Myasthenia Gravis"
        },
        {
            "Company": "Juno Therapeutics (Part of Bristol-Myers Squibb)",
            "GenericDrug": "NULL",
            "OtherDrug": "JTCR-016",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "WT1",
            "Disease": "Acute Myeloid Leukemia"
        },
        {
            "Company": "Mustang Bio (Part of Fortress Biotech)",
            "GenericDrug": "NULL",
            "OtherDrug": "Autologous IL13(EQ)BBzeta/CD19t+ TCM-enriched T cells",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "Glioblastoma"
        },
        {
            "Company": "Shanghai GeneChem",
            "GenericDrug": "NULL",
            "OtherDrug": "Anti-CD19 CAR-T Cells",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "B-Cell Leukemia"
        },
        {
            "Company": "Shanghai GeneChem",
            "GenericDrug": "NULL",
            "OtherDrug": "TAI-GPC3 CAR-T Cells",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "GPC3",
            "Disease": "Hepatocelllular Carcinoma"
        },
        {
            "Company": "Eureka Therapeutics",
            "GenericDrug": "NULL",
            "OtherDrug": "ET1402L1-CART ET 140202 ET1402L1-ARTEMIS™2",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "Alpha Fetoprotein",
            "Disease": "Hepatocellular carcinoma"
        },
        {
            "Company": "Beijing Immunochina Medical Science & Technology",
            "GenericDrug": "NULL",
            "OtherDrug": "IM19 CAR-T",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD 19",
            "Disease": "Non-Hodgkin Lymphoma"
        },
        {
            "Company": "Pregene",
            "GenericDrug": "NULL",
            "OtherDrug": "PD-1 CAR19",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD 19",
            "Disease": "Relapsed Non Hodgkin Lymphoma"
        },
        {
            "Company": "Shanghai GeneChem",
            "GenericDrug": "NULL",
            "OtherDrug": "TAI-GPC3 CAR-T Cells",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "GPC3",
            "Disease": "Hepatocelllular Carcinoma"
        },
        {
            "Company": "Nanjing Legend Biotechnology Co.",
            "GenericDrug": "NULL",
            "OtherDrug": "LCAR-C182A/LCAR-C182B/LCAR-C182C",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "Claudin18.2",
            "Disease": "NULL"
        },
        {
            "Company": "Intrexon",
            "GenericDrug": "NULL",
            "OtherDrug": "PRGN-3006",
            "Origin": "U.S.",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD33",
            "Disease": "Leukemia, Acute Myelogenou;Myelodysplastic Syndrome"
        },
        {
            "Company": "Gracell Biotechnologies",
            "GenericDrug": "NULL",
            "OtherDrug": "GC022 ",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "B-cell Acute Lymphoblastic Leukemia"
        },
        {
            "Company": "Wuhan Bio-Raid",
            "GenericDrug": "NULL",
            "OtherDrug": "CS1 CAR-T",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "CS1",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Wuhan Yungu Biomedical Technology Co.",
            "GenericDrug": "NULL",
            "OtherDrug": "Anti-gp120 CAR-T",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "gp120",
            "Disease": "HIV"
        },
        {
            "Company": "Allife Medical Science",
            "GenericDrug": "NULL",
            "OtherDrug": "Anti-CD22 CAR NK cell therapy",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19/CD22",
            "Disease": "B-cell Lymphoma"
        },
        {
            "Company": "Servier",
            "GenericDrug": "NULL",
            "OtherDrug": "ALLO-501",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Advanced Lymphoid Malignancies"
        },
        {
            "Company": "Shanghai Unicar-Therapy Bio-med",
            "GenericDrug": "NULL",
            "OtherDrug": "Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Hodgkin's/Non-Hodgkin's Lymphom"
        },
        {
            "Company": "BioNtech",
            "GenericDrug": "NULL",
            "OtherDrug": "BNT-211",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CLDN-6",
            "Disease": "Non-Small Cell Lung Cancer"
        },
        {
            "Company": "BioNtech",
            "GenericDrug": "NULL",
            "OtherDrug": "BNT-212",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "Pancreatic Cancer"
        },
        {
            "Company": "Sinobioway Cell Therapy",
            "GenericDrug": "NULL",
            "OtherDrug": "CD19-targeted CAR-T cells",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "Not Applicable",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Lymphoma, Non-Hodgkin's"
        },
        {
            "Company": "Shanghai Unicar-Therapy Biomed",
            "GenericDrug": "NULL",
            "OtherDrug": "CD19 CAR-T cells",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "B-cell Acute Lymphocytic Leukemia"
        },
        {
            "Company": "Autolus Limited",
            "GenericDrug": "NULL",
            "OtherDrug": "AUTO1",
            "Origin": "UK",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Acute Lymphoblastic Leukemia"
        },
        {
            "Company": "Bluebied Bio",
            "GenericDrug": "NULL",
            "OtherDrug": "bb21217",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Sensei Biotherapeutics",
            "GenericDrug": "NULL",
            "OtherDrug": "PAN-301-1",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "Human Aspartyl (Asparaginyl) beta-hydroxylase (HAAH)",
            "Disease": "Prostate Cancer "
        },
        {
            "Company": "Takara Bio",
            "GenericDrug": "NULL",
            "OtherDrug": "CD19-CAR T",
            "Origin": "Japan",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Lymphoblastic Leukemia, Acute Adult"
        },
        {
            "Company": "Cellular Biomedicine Group (CBMG)",
            "GenericDrug": "NULL",
            "OtherDrug": "C-CAR088 (Anti-BCMA CAR-T cell therapy)",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "TNF receptor superfamily member 17",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Bluebird Bio",
            "GenericDrug": "Idecabtagene Vicleucel",
            "OtherDrug": "Anti- BCMA CAR-T Therapy",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Cellectis",
            "GenericDrug": "NULL",
            "OtherDrug": "UCART-123",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD123",
            "Disease": "Acute Myeloid Leukemia"
        },
        {
            "Company": "Cellectis",
            "GenericDrug": "NULL",
            "OtherDrug": "UCART-123",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD123",
            "Disease": "Blastic Plasmacytoid Dendritic Cell Neoplasm"
        },
        {
            "Company": "Cellectis",
            "GenericDrug": "NULL",
            "OtherDrug": "UCART-123",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD123",
            "Disease": "Blastic Plasmacytoid Dendritic Cell Neoplasm"
        },
        {
            "Company": "Cellectis",
            "GenericDrug": "NULL",
            "OtherDrug": "UCART-22",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "B-cell Acute Lymphoblastic Leukemia"
        },
        {
            "Company": "Cellectis",
            "GenericDrug": "NULL",
            "OtherDrug": "UCART-CS1",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Gilead Sciences/Kite Pharma",
            "GenericDrug": "Axicabtagene Ciloleuce",
            "OtherDrug": "N/A",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Diffuse Large B-cell Lymphoma"
        },
        {
            "Company": "Celyad",
            "GenericDrug": "NULL",
            "OtherDrug": "CYAD-01",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "NKG2D-Ligands",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Celgene",
            "GenericDrug": "Idecabtagene Vicleucel",
            "OtherDrug": "bb2121",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Bellicum",
            "GenericDrug": "NULL",
            "OtherDrug": "BPX-601",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "PSCA",
            "Disease": "NULL"
        },
        {
            "Company": "Cellectis",
            "GenericDrug": "NULL",
            "OtherDrug": "UCART-123",
            "Origin": "UK",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD123",
            "Disease": "Acute myeloid leukaemia"
        },
        {
            "Company": "Cellectis",
            "GenericDrug": "NULL",
            "OtherDrug": "UCART-123",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD123",
            "Disease": "Acute Myeloid Leukemia"
        },
        {
            "Company": "Mustang Bio (Part of Fortress Biotech)",
            "GenericDrug": "NULL",
            "OtherDrug": "C134",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "NULL"
        },
        {
            "Company": "Cellular Biomedicine Group (CBMG)",
            "GenericDrug": "NULL",
            "OtherDrug": "C-CAR011 (anti-CD19)",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Acute Lymphoblastic Leukemia"
        },
        {
            "Company": "Bluebird Bio",
            "GenericDrug": "Idecabtagene Vicleucel",
            "OtherDrug": "Anti- BCMA CAR-T Therapy",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Celyad",
            "GenericDrug": "NULL",
            "OtherDrug": "CAR-NKG2D",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NKG2D-Ligands",
            "Disease": "Solid Tumors"
        },
        {
            "Company": "Gilead Sciences/Kite Pharma",
            "GenericDrug": "Axicabtagene Ciloleuce",
            "OtherDrug": "KTE-X19",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "Acute Lymphoblastic Leukemia"
        },
        {
            "Company": "Celgene",
            "GenericDrug": "Idecabtagene Vicleucel",
            "OtherDrug": "bb2121",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "United States",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Primary Central Nervous System Lymphoma"
        },
        {
            "Company": "Cellular Biomedicine Group (CBMG)",
            "GenericDrug": "NULL",
            "OtherDrug": "C-CAR011 (anti-CD19)",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Diffuse Large B-cell Lymphoma"
        },
        {
            "Company": "Cellular Biomedicine Group (CBMG)",
            "GenericDrug": "NULL",
            "OtherDrug": "C-CAR011 (anti-CD19)",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Mantle Cell Lymphoma"
        },
        {
            "Company": "Cellular Biomedicine Group (CBMG)",
            "GenericDrug": "NULL",
            "OtherDrug": "C-CAR011 (anti-CD19)",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "Not Applicable",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Acute Lymphoblastic Leukemia"
        },
        {
            "Company": "Cellular Biomedicine Group (CBMG)",
            "GenericDrug": "NULL",
            "OtherDrug": "C-CAR011 (anti-CD19)",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "Not Applicable",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "NULL"
        },
        {
            "Company": "Cellular Biomedicine Group (CBMG)",
            "GenericDrug": "NULL",
            "OtherDrug": "C-CAR088 (Anti-BCMA CAR-T cell therapy)",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "TNF receptor superfamily member 17",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Cellectis",
            "GenericDrug": "NULL",
            "OtherDrug": "C-119",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "B-cell Acute Lymphoblastic Leukemia"
        },
        {
            "Company": "Cellectis",
            "GenericDrug": "NULL",
            "OtherDrug": "UCART-22",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD22",
            "Disease": "B-cell Acute Lymphoblastic Leukemia"
        },
        {
            "Company": "Cellectis",
            "GenericDrug": "NULL",
            "OtherDrug": "UCART-CS1",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CS1",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Gilead Sciences/Kite Pharma",
            "GenericDrug": "Axicabtagene Ciloleuce",
            "OtherDrug": "KTE-X19",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "Chronic Lymphocytic Leukemia"
        },
        {
            "Company": "Celyad",
            "GenericDrug": "NULL",
            "OtherDrug": "CYAD-01",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NKG2D-Ligands",
            "Disease": "Acute Myeloid Leukemia"
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "United States",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Chronic Lymphocytic Leukemia"
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "Australia",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Mantle Cell Lymphoma"
        },
        {
            "Company": "Janssen/Legend Biotech (Nanjing Legend)",
            "GenericDrug": "NULL",
            "OtherDrug": "JNJ-4528",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Celyad",
            "GenericDrug": "NULL",
            "OtherDrug": "CAR-NKG2D",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "NKG2D-Ligands",
            "Disease": "Acute Myeloid Leukemia"
        },
        {
            "Company": "CRISPR Therapeutics",
            "GenericDrug": "NULL",
            "OtherDrug": "CTX-101",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "B-cell Lymphoma"
        },
        {
            "Company": "Minerva",
            "GenericDrug": "NULL",
            "OtherDrug": "Anti-MUC1* CAR-T",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NS",
            "Target": "cell surface associated",
            "Disease": "Metastatic Breast Cancer"
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "United States",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Pancreatic  "
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "United States",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Acute Lymphocytic Leukemia"
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Colorectal"
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "Y",
            "Target": "CD19",
            "Disease": "Chronic Lymphocytic Leukemia"
        },
        {
            "Company": "Janssen/Legend Biotech (Nanjing Legend)",
            "GenericDrug": "NULL",
            "OtherDrug": "JNJ-4528",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Celyad",
            "GenericDrug": "NULL",
            "OtherDrug": "CYAD-02",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NKG2D-Ligands",
            "Disease": "Acute Myeloid Leukemia"
        },
        {
            "Company": "Celyad",
            "GenericDrug": "NULL",
            "OtherDrug": "CYAD-01",
            "Origin": "Belgium",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NKG2D",
            "Disease": "Colon Cancer Liver Metastasis"
        },
        {
            "Company": "Celyad",
            "GenericDrug": "NULL",
            "OtherDrug": "CYAD-01",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NKG2D-Ligands",
            "Disease": "Acute Myelogenous Leukemia"
        },
        {
            "Company": "Wellington Zhaotai Therapies Limited",
            "GenericDrug": "NULL",
            "OtherDrug": "1928T2z CAR-T",
            "Origin": "New Zealand",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Diffuse Large B-cell Lymphoma (DLBCL), Lymphomas Non-Hodgkin's B-Cell, Primary Mediastinal B-cell Lymphoma (PMBCL), Transformed Follicular Lymphoma (TFL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL)"
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "United States",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Diffuse Large B-Cell Lymphoma; Follicular Lymphoma"
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "United States",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma"
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "Australia; Austria; Belgium; Canada; Denmark; Finland; France; Germany; Italy; Japan; Netherlands; Norway; Spain; Sweden; United Kingdom; United States",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), gray zone lymphoma (GZL), and follicular lymphoma (FL)"
        },
        {
            "Company": "Amgen",
            "GenericDrug": "NULL",
            "OtherDrug": "AMG-553",
            "Origin": "United States",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "Acute Myeloid Leukemia"
        },
        {
            "Company": "Allife Medical Science and Technology",
            "GenericDrug": "NULL",
            "OtherDrug": "BCMA-CAR-T ",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Celyad",
            "GenericDrug": "NULL",
            "OtherDrug": "CAR-NKG2D",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NKG2D-Ligands",
            "Disease": "Acute Myeloid Leukemia"
        },
        {
            "Company": "Helix BioPharma",
            "GenericDrug": "NULL",
            "OtherDrug": "L-DOS47",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "Lung Adenocarcinoma"
        },
        {
            "Company": "Kite Pharma (Now Gilead Sciences)",
            "GenericDrug": "Axicabtagene ciloleucel ",
            "OtherDrug": "CD19 CAR-T Therapy",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "NULL"
        },
        {
            "Company": "Juno Therapeutics (Part of Bristol-Myers Squibb)",
            "GenericDrug": "Orvacabtagene Autoleucel",
            "OtherDrug": "BCMA targeting CAR T cell therapy",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "United States",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Acute Lymphocytic Leukemia"
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "United States",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Diffuse Large B-Cell Lymphoma; Follicular lymphoma; Mantle Cell Lymphoma"
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "Australia; Austria; Canada; China; France; Germany; Hong Kong; Italy; Japan; Netherlands; Norway; Singapore; Spain; Switzerland; United Kingdom; United States",
            "Partner": "NULL",
            "Phase": "III",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "NULL"
        },
        {
            "Company": "Kite Pharma (Now Gilead Sciences)",
            "GenericDrug": "Axicabtagene ciloleucel ",
            "OtherDrug": "CD19 CAR-T Therapy",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Cytokine Release Syndrome"
        },
        {
            "Company": "Kite Pharma (Now Gilead Sciences)",
            "GenericDrug": "Axicabtagene ciloleucel ",
            "OtherDrug": "CD19 CAR-T Therapy",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Non-Hodgkin's Lymphoma"
        },
        {
            "Company": "Kite Pharma (Now Gilead Sciences)",
            "GenericDrug": "Axicabtagene ciloleucel ",
            "OtherDrug": "CD19 CAR-T Therapy",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Cytokine Release Syndrome"
        },
        {
            "Company": "Kite Pharma (Now Gilead Sciences)",
            "GenericDrug": "Axicabtagene ciloleucel ",
            "OtherDrug": "CD19 CAR-T Therapy",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "NULL"
        },
        {
            "Company": "Nanjing Iaso Biotherapeutics Co",
            "GenericDrug": "NULL",
            "OtherDrug": "Anti-BCMA CAR-T",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Plasma Cell Tumors"
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "United States",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Acute Lymphocytic Leukemia; Diffuse Large B-Cell Lymphoma"
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "United States",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Acute Lymphocytic Leukemia"
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "Japan",
            "Partner": "NULL",
            "Phase": "III",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Acute Lymphocytic Leukemia; Non-Hodgkin's Lymphoma"
        },
        {
            "Company": "Kite Pharma (Now Gilead Sciences)",
            "GenericDrug": "Axicabtagene ciloleucel ",
            "OtherDrug": "CD19 CAR-T Therapy",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Non-Hodgkin's Lymphoma"
        },
        {
            "Company": "Kite Pharma (Now Gilead Sciences)",
            "GenericDrug": "Axicabtagene ciloleucel ",
            "OtherDrug": "CD19 CAR-T Therapy",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "III",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Diffuse Large B Cell Lymphoma"
        },
        {
            "Company": "Marino Biotechnology",
            "GenericDrug": "NULL",
            "OtherDrug": "Anti-EGFRvIII CAR T",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "EGFRvIII",
            "Disease": "Glioblastoma Multiforme"
        },
        {
            "Company": "CARsgen",
            "GenericDrug": "NULL",
            "OtherDrug": "CSG-GPC3",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "GPC3",
            "Disease": "Breast Cancer"
        },
        {
            "Company": "CARsgen",
            "GenericDrug": "NULL",
            "OtherDrug": "CSG-GPC3",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "GPC3",
            "Disease": "Advanced hepatocellular carcinoma"
        },
        {
            "Company": "CARsgen",
            "GenericDrug": "NULL",
            "OtherDrug": "CSG-GPC3",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "GPC3",
            "Disease": "Lung squamous cell carcinoma"
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "Australia; Austria; Canada; France; Germany; Italy; Japan; Netherlands; Norway; United States",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "Y",
            "Target": "CD19",
            "Disease": "Autoimmune/Inflammation: Cytokine Release Syndrome (CRS); Diffuse Large B-Cell Lymphoma"
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "United States",
            "Partner": "NULL",
            "Phase": "III",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Non-Hodgkin's Lymphoma"
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "Japan",
            "Partner": "NULL",
            "Phase": "III",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Acute Lymphocytic Leukemia"
        },
        {
            "Company": "Kite Pharma (Now Gilead Sciences)",
            "GenericDrug": "Axicabtagene ciloleucel ",
            "OtherDrug": "CD19 CAR-T Therapy",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Non-Hodgkin's Lymphoma"
        },
        {
            "Company": "Kite Pharma (Now Gilead Sciences)",
            "GenericDrug": "Axicabtagene ciloleucel ",
            "OtherDrug": "CD19 CAR-T Therapy",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Large B-cell lymphoma"
        },
        {
            "Company": "Kite Pharma (Now Gilead Sciences)",
            "GenericDrug": "Axicabtagene ciloleucel ",
            "OtherDrug": "CD19 CAR-T Therapy",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Diffuse Large B-cell Lymphoma"
        },
        {
            "Company": "Milyenyi Biotec",
            "GenericDrug": "NULL",
            "OtherDrug": "CD-19 CAR-T cell therapy",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Precursor B-Lymphoblastic Lymphoma/Leukaemia Refractory"
        },
        {
            "Company": "Autolus Limited",
            "GenericDrug": "NULL",
            "OtherDrug": "Auto-2 ",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Autolus Limited",
            "GenericDrug": "NULL",
            "OtherDrug": "Auto-3",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Diffuse Large B Cell Lymphoma"
        },
        {
            "Company": "Autolus Limited",
            "GenericDrug": "NULL",
            "OtherDrug": "Auto-4",
            "Origin": "UK",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "TRBC1",
            "Disease": "T cell non-Hodgkin Lymphoma"
        },
        {
            "Company": "Cellectis",
            "GenericDrug": "NULL",
            "OtherDrug": "UCART-19",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "B-cell Acute Lymphoblastic Leukemia"
        },
        {
            "Company": "Cellectis",
            "GenericDrug": "NULL",
            "OtherDrug": "UCART-19",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "B-cell Acute Lymphoblastic Leukemia"
        },
        {
            "Company": "Miltenyi Biotec",
            "GenericDrug": "NULL",
            "OtherDrug": "Anti-CD20/19 CAR T cells",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD20 and CD19",
            "Disease": "B-cell Non-Hodgkin Lymphoma"
        },
        {
            "Company": "Cellular Biomedicine Group (CBMG)",
            "GenericDrug": "NULL",
            "OtherDrug": "C-CAR011 (anti-CD19)",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Non-Hodgkin Lymphoma"
        },
        {
            "Company": "Cellular Biomedicine Group (CBMG)",
            "GenericDrug": "NULL",
            "OtherDrug": "C-CAR066 (Anti-CD20 CAR-T cell therapy)",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "B-cell Lymphoma"
        },
        {
            "Company": "Milyenyi Biotec",
            "GenericDrug": "NULL",
            "OtherDrug": "CD-19 CAR-T cell therapy",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD19 and CD20",
            "Disease": "Diffuse Large B-cell Lymphoma"
        },
        {
            "Company": "CARsgen",
            "GenericDrug": "NULL",
            "OtherDrug": "CSG-GPC3",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "Hepatocellular carcinoma"
        },
        {
            "Company": "CARsgen",
            "GenericDrug": "NULL",
            "OtherDrug": "CAR-BCMA T (CT-053)",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "CARsgen",
            "GenericDrug": "NULL",
            "OtherDrug": "CAR-BCMA T (CT-053)",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "Ib",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Juno Therapeutics (Part of Bristol-Myers Squibb)",
            "GenericDrug": "Lisocabtagene Maraleucel",
            "OtherDrug": "CD19-Specific CAR-T Cell Therapy",
            "Origin": "Japan",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Diffuse Large B-cell Lymphoma"
        },
        {
            "Company": "Juno Therapeutics (Part of Bristol-Myers Squibb)",
            "GenericDrug": "Lisocabtagene Maraleucel",
            "OtherDrug": "CD19-Specific CAR-T Cell Therapy",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "B-cell Lymphoma"
        },
        {
            "Company": "MaxCyte",
            "GenericDrug": "NULL",
            "OtherDrug": "CARMA-M01",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "Mesothelin",
            "Disease": "NULL"
        },
        {
            "Company": "iCarTAB BioMed",
            "GenericDrug": "NULL",
            "OtherDrug": " CD19-CAR-T cells",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Chronic B-Cell Lymphocytic Leukemia"
        },
        {
            "Company": "PersonGen Biomedicine (Suzhou) Co.",
            "GenericDrug": "NULL",
            "OtherDrug": "MUC1 CAR-pNK cell therapy",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": " I/II",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "Hepatocellular carcinoma"
        },
        {
            "Company": "CARsgen",
            "GenericDrug": "NULL",
            "OtherDrug": "CSG-GPC3",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "Advanced hepatocellular carcinoma"
        },
        {
            "Company": "Fapon Biotech",
            "GenericDrug": "NULL",
            "OtherDrug": "UCART-19",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Acute Lymphocytic Leukemia"
        },
        {
            "Company": "iCarTAB BioMed",
            "GenericDrug": "NULL",
            "OtherDrug": " CAR-T cell therapy",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "leukemia, lymphoma"
        },
        {
            "Company": "Juno Therapeutics (Part of Bristol-Myers Squibb)",
            "GenericDrug": "Lisocabtagene Maraleucel",
            "OtherDrug": "CD19-Specific CAR-T Cell Therapy",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "CD 19+ Acute Leukemia"
        },
        {
            "Company": "Juno Therapeutics (Part of Bristol-Myers Squibb)",
            "GenericDrug": "Lisocabtagene Maraleucel",
            "OtherDrug": "CD19-Specific CAR-T Cell Therapy",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "B-Cell Leukemia"
        },
        {
            "Company": "Juno Therapeutics (Part of Bristol-Myers Squibb)",
            "GenericDrug": "Lisocabtagene Maraleucel",
            "OtherDrug": "CD19-Specific CAR-T Cell Therapy",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Chronic B-Cell Lymphocytic Leukemia"
        },
        {
            "Company": "Hrain Biotechnology",
            "GenericDrug": "NULL",
            "OtherDrug": "anti-MESO CAR-T ",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "Ovarian Cancer"
        },
        {
            "Company": "Celgene/Juno Therapeutics",
            "GenericDrug": "NULL",
            "OtherDrug": " JCAR-020",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "MUC-16/IL-12",
            "Disease": "Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer"
        },
        {
            "Company": "Celgene/Juno Therapeutics",
            "GenericDrug": "Orvacabtagene Autoleucel",
            "OtherDrug": "JCARH125",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Opus Bio",
            "GenericDrug": "NULL",
            "OtherDrug": "CAR-T Therapy",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD22",
            "Disease": "Follicular Lymphoma"
        },
        {
            "Company": "Cellular Biomedicine Group (CBMG)",
            "GenericDrug": "NULL",
            "OtherDrug": "C-CAR066 (Anti-CD20 CAR-T cell therapy)",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "NULL"
        },
        {
            "Company": "Cellectis",
            "GenericDrug": "NULL",
            "OtherDrug": "C-119",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Advanced Lymphoid Malignancies"
        },
        {
            "Company": "Gilead Sciences/Kite Pharma",
            "GenericDrug": "NULL",
            "OtherDrug": "KITE-585",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Timmune Biotech",
            "GenericDrug": "NULL",
            "OtherDrug": "GPA-TriMAR-T",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Malignant Melanoma"
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "Austria; Canada; Germany; United States",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Diffuse Large B-cell Lymphoma"
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "United States",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Acute Lymphocytic Leukemia"
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "Belgium; Canada; Denmark; Finland; France; Germany; Italy; Netherlands; Norway; Spain; Sweden; United Kingdom; United States",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Acute Lymphocytic Leukemia"
        },
        {
            "Company": "Amgen",
            "GenericDrug": "NULL",
            "OtherDrug": "AMG-119",
            "Origin": "United States",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "Small Cell Lung Cancer"
        },
        {
            "Company": "Autolus Limited",
            "GenericDrug": "NULL",
            "OtherDrug": "Auto-2 ",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "BoYuan RunSheng Pharma",
            "GenericDrug": "NULL",
            "OtherDrug": "B7-H3 CAR-T Therapy",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "B7-H3",
            "Disease": "Glioblastoma"
        },
        {
            "Company": "Sensei Biotherapeutics",
            "GenericDrug": "NULL",
            "OtherDrug": "PAN-301-1",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "Human Aspartyl (Asparaginyl) beta-hydroxylase (HAAH)",
            "Disease": "NULL"
        },
        {
            "Company": "TC Biopharm",
            "GenericDrug": "NULL",
            "OtherDrug": "ImmuniCell",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NS",
            "Target": "Unspecified",
            "Disease": "Malignant Melanoma, Non-small Cell Lung Cancer, Renal Cell Cancer"
        },
        {
            "Company": "Bluebird Bio",
            "GenericDrug": "Idecabtagene Vicleucel",
            "OtherDrug": "Anti- BCMA CAR-T Therapy",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "III",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Gilead Sciences/Kite Pharma",
            "GenericDrug": "Axicabtagene Ciloleuce",
            "OtherDrug": "N/A",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Large B-cell lymphoma"
        },
        {
            "Company": "CARsgen",
            "GenericDrug": "NULL",
            "OtherDrug": "CAR-CLD18",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "NULL"
        },
        {
            "Company": "CARsgen",
            "GenericDrug": "NULL",
            "OtherDrug": "CSG-CD19",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "B-cell Non-Hodgkin Lymphoma"
        },
        {
            "Company": "Juno Therapeutics (Part of Bristol-Myers Squibb)",
            "GenericDrug": "Lisocabtagene Maraleucel",
            "OtherDrug": "CD19-Specific CAR-T Cell Therapy",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Diffuse Large B Cell Lymphoma"
        },
        {
            "Company": "Juno Therapeutics (Part of Bristol-Myers Squibb)",
            "GenericDrug": "Lisocabtagene Maraleucel",
            "OtherDrug": "CD19-Specific CAR-T Cell Therapy",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "CD 19+ Acute Leukemia"
        },
        {
            "Company": "JW Therapeutics",
            "GenericDrug": "NULL",
            "OtherDrug": " JWCAR029",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Diffuse Large B Cell Lymphoma"
        },
        {
            "Company": "Qilu Cell Therapy Technology Co.",
            "GenericDrug": "NULL",
            "OtherDrug": " CD19 specific CAR T cells",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": " I/II",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "NULL"
        },
        {
            "Company": "Beijing Doing Biomedical Technology Co.",
            "GenericDrug": "NULL",
            "OtherDrug": " CD19-CAR T cells",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Acute Lymphoblastic Leukemia"
        },
        {
            "Company": "Cartesian Therapeutics",
            "GenericDrug": "NULL",
            "OtherDrug": "Descartes-011",
            "Origin": "United States",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Juno Therapeutics (Part of Bristol-Myers Squibb)",
            "GenericDrug": "Orvacabtagene Autoleucel",
            "OtherDrug": "BCMA targeting CAR T cell therapy",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Mustang Bio (Part of Fortress Biotech)",
            "GenericDrug": "NULL",
            "OtherDrug": "Anti-CD123-CAR/CD28-costimulatory retroviral vector-transduced",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD123",
            "Disease": "Acute Myeloid Leukemia"
        },
        {
            "Company": "Beijing Immunochina Medical Science & Technology",
            "GenericDrug": "NULL",
            "OtherDrug": "IM19 CAR-T",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD 19",
            "Disease": "B-cell Acute Lymphoblastic Leukemia"
        },
        {
            "Company": "Beijing Immunochina Medical Science & Technology",
            "GenericDrug": "NULL",
            "OtherDrug": "IM19 CAR-T",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD 19",
            "Disease": "Hematological Malignancies"
        },
        {
            "Company": "Bioceltech Therapeutics",
            "GenericDrug": "NULL",
            "OtherDrug": "CD19-CAR-T Cell Therapy",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "B-cell Acute Lymphoblastic Leukemia"
        },
        {
            "Company": "Mustang Bio (Part of Fortress Biotech)",
            "GenericDrug": "NULL",
            "OtherDrug": "MB-104",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CS1",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Intrexon",
            "GenericDrug": "NULL",
            "OtherDrug": "PRGN-3005",
            "Origin": "U.S.",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "Ovarian Cancer"
        },
        {
            "Company": "Shanghai Cell Therapy Engineering Technology Research Center Group Co., Ltd.",
            "GenericDrug": "NULL",
            "OtherDrug": "CD19 CART",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "B cell Lymphoma, Transformed Lymphoma, Primary Mediastinal Large B Cell Lymphoma"
        },
        {
            "Company": "Wuhan Bio-Raid",
            "GenericDrug": "NULL",
            "OtherDrug": "Anti-CD22 CAR-T cell therapy",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Chronic Lymphocytic Leukemia"
        },
        {
            "Company": "Mustang Bio (Part of Fortress Biotech)",
            "GenericDrug": "NULL",
            "OtherDrug": "Autologous IL13(EQ)BBzeta/CD19t+ TCM-enriched T cells",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "Glioblastoma"
        },
        {
            "Company": "Nanjing KAEDI Biotech",
            "GenericDrug": "NULL",
            "OtherDrug": "Anti-CD19 CAR-T cell therapy",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "B-cell Acute Lymphoblastic Leukemia"
        },
        {
            "Company": "Nanjing KAEDI Biotech",
            "GenericDrug": "NULL",
            "OtherDrug": "KD-025 2nd",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "NKG2D",
            "Disease": "Hepatocellular carcinoma"
        },
        {
            "Company": "Nohla Therapeutics",
            "GenericDrug": "NULL",
            "OtherDrug": "NLA-102",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "Acute Myelogenous Leukemia"
        },
        {
            "Company": "Pregene",
            "GenericDrug": "NULL",
            "OtherDrug": "EGFR -IL12 -CART",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "EGFR",
            "Disease": "Metastatic Colorectal Cancer"
        },
        {
            "Company": "Mustang Bio (Part of Fortress Biotech)",
            "GenericDrug": "NULL",
            "OtherDrug": "HER2 chimaeric antigen receptor therapy",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "HER-2",
            "Disease": "NULL"
        },
        {
            "Company": "Tmunity Therapeutics",
            "GenericDrug": "NULL",
            "OtherDrug": "Tn MUC-1 CAR-T therapy",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "TnMUC1",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Baxalta (now Takeda)",
            "GenericDrug": "NULL",
            "OtherDrug": "PBCAR0191-01",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia"
        },
        {
            "Company": "Shanghai Bioray Laboratory",
            "GenericDrug": "NULL",
            "OtherDrug": "BCMA-UCART",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "Not Applicable",
            "PivotalIntent": "NS",
            "Target": "BCMA-expressing MM tumor cells",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "China Immunotech Co., Ltd.",
            "GenericDrug": "NULL",
            "OtherDrug": "CD19 CAR-T",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "B-Cell Malignancy"
        },
        {
            "Company": "Anixa Biosciences",
            "GenericDrug": "NULL",
            "OtherDrug": "CAR-T Therapy",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "NULL"
        },
        {
            "Company": "Celyad",
            "GenericDrug": "NULL",
            "OtherDrug": "CAR-NKG2D",
            "Origin": "Belgium",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NKG2D",
            "Disease": "Colon Cancer Liver Metastasis"
        },
        {
            "Company": "Kite Pharma (Now Gilead Sciences)",
            "GenericDrug": "Axicabtagene ciloleucel ",
            "OtherDrug": "CD19 CAR-T Therapy",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Diffuse Large B-cell Lymphoma"
        },
        {
            "Company": "Henan Hualong Biotechnology Co., Ltd",
            "GenericDrug": "NULL",
            "OtherDrug": "Cord Blood Derived CAR-T Cells",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "NULL"
        },
        {
            "Company": "Juno Therapeutics (Part of Bristol-Myers Squibb)",
            "GenericDrug": "Orvacabtagene Autoleucel",
            "OtherDrug": "BCMA targeting CAR T cell therapy",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "Australia; Austria; Belgium; Canada; France; Germany; Italy; Japan; Netherlands; Norway; Spain; Taiwan; United Kingdom; United States",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Follicular Lymphoma"
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "Australia; Austria; Belgium; Canada; France; Germany; Italy; Netherlands; Norway; Spain; United States",
            "Partner": "NULL",
            "Phase": "II/III",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Acute Lymphocytic Leukemia; Chronic Lymphocytic Leukemia; Non-Hodgkin's Lymphoma; Multiple Myeloma"
        },
        {
            "Company": "Kite Pharma (Now Gilead Sciences)",
            "GenericDrug": "Axicabtagene ciloleucel ",
            "OtherDrug": "CD19 CAR-T Therapy",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Non-Hodgkin's Lymphoma"
        },
        {
            "Company": "Kite Pharma (Now Gilead Sciences)",
            "GenericDrug": "Axicabtagene ciloleucel ",
            "OtherDrug": "CD19 CAR-T Therapy",
            "Origin": "Japan",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Non-Hodgkin's Lymphoma"
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "United States",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Multiple Myeloma, Acute biphenotypic leukemia, Diffuse Large B-Cell Lymphoma"
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Acute Lymphocytic Leukemia"
        },
        {
            "Company": "Janssen/Legend Biotech (Nanjing Legend)",
            "GenericDrug": "NULL",
            "OtherDrug": "JNJ-4528",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Beijing Biohealthcare",
            "GenericDrug": "NULL",
            "OtherDrug": "CART-20",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "B-cell Lymphoma"
        },
        {
            "Company": "CASI/Juventas",
            "GenericDrug": "NULL",
            "OtherDrug": "CNCT-19",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Acute Lymphocytic Leukemia"
        },
        {
            "Company": "CASI/Juventas",
            "GenericDrug": "NULL",
            "OtherDrug": "CNCT-19",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Acute Lymphocytic Leukemia"
        },
        {
            "Company": "Celyad",
            "GenericDrug": "NULL",
            "OtherDrug": "CAR-NKG2D",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "NKG2D-Ligands",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Kite Pharma (Now Gilead Sciences)",
            "GenericDrug": "Axicabtagene ciloleucel ",
            "OtherDrug": "CD19 CAR-T Therapy",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Diffuse Large B-cell Lymphoma"
        },
        {
            "Company": "Helix BioPharma",
            "GenericDrug": "NULL",
            "OtherDrug": "L-DOS47",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "Non-Small Cell Lung Cancer"
        },
        {
            "Company": "Formula Pharmaceuticals",
            "GenericDrug": "NULL",
            "OtherDrug": "CIK-CAR.CD19",
            "Origin": "Italy",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "Acute Lymphoblastic Leukemia"
        },
        {
            "Company": "Ziopharm Oncology",
            "GenericDrug": "NULL",
            "OtherDrug": "CD33 CAR-T Therapy",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD33",
            "Disease": "Acute Myeloid Leukemia"
        },
        {
            "Company": "Cellectis",
            "GenericDrug": "NULL",
            "OtherDrug": "C-119",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "B-cell Acute Lymphoblastic Leukemia"
        },
        {
            "Company": "Heibei Sen Lang Biotechnology",
            "GenericDrug": "NULL",
            "OtherDrug": "CD19-CAR T",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "B-Cell Leukemia"
        },
        {
            "Company": "Shanghai Unicar-Therapy Bio-med",
            "GenericDrug": "SSCAR-060",
            "OtherDrug": "Chimeric antigen receptor T cell (Evaluate the efficacy and safety of targeted Mesothelin/PSCA/CEA/HER2/MUC1/",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "mesothein",
            "Disease": "Pancreatic Cancer"
        },
        {
            "Company": "Hunan Zhaotai Yongren Medical Innovation Co/Guangdong Zhaotai InVivo Biomedicine Co.",
            "GenericDrug": "NULL",
            "OtherDrug": "CAR-T",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NS",
            "Target": "HER2",
            "Disease": "Lung Cancer"
        },
        {
            "Company": "iCarTAB BioMed",
            "GenericDrug": "NULL",
            "OtherDrug": "CD22 CAR-T",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD22",
            "Disease": "b cell malignancy"
        },
        {
            "Company": "Sinobioway Cell Therapy",
            "GenericDrug": "NULL",
            "OtherDrug": "CAR-T",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Lymphoma, Non-Hodgkin's"
        },
        {
            "Company": "Shanghai Unicar-Therapy Biomed",
            "GenericDrug": "NULL",
            "OtherDrug": "CART-19/22",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NS",
            "Target": "NULL",
            "Disease": "Leukemia, B-cell"
        },
        {
            "Company": "Juno Therapeutics (Part of Bristol-Myers Squibb)",
            "GenericDrug": "NULL",
            "OtherDrug": "CAR Modified T-Cells",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Acute Lymphoblastic Leukemia"
        },
        {
            "Company": "Mustang Bio (Part of Fortress Biotech)",
            "GenericDrug": "NULL",
            "OtherDrug": "Anti-CD123-CAR/CD28-costimulatory retroviral vector-transduced",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD123",
            "Disease": "Acute Myelogenous Leukemia"
        },
        {
            "Company": "Mustang Bio (Part of Fortress Biotech)",
            "GenericDrug": "NULL",
            "OtherDrug": "Anti-CD123-CAR/CD28-costimulatory retroviral vector-transduced",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD123",
            "Disease": "Acute Myeloid Leukemia"
        },
        {
            "Company": "Pregene",
            "GenericDrug": "NULL",
            "OtherDrug": "BCMA CAR-T",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "TNFRSF17",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Mustang Bio (Part of Fortress Biotech)",
            "GenericDrug": "NULL",
            "OtherDrug": "Autologous anti-PSCA(dCH2)BBz-CAR T-cell therapy",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "PSCA",
            "Disease": "NULL"
        },
        {
            "Company": "Mustang Bio (Part of Fortress Biotech)",
            "GenericDrug": "NULL",
            "OtherDrug": "Autologous anti-PSCA(dCH2)BBz-CAR T-cell therapy",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "PSCA",
            "Disease": "Prostate Cancer "
        },
        {
            "Company": "Shanghai Longyao Biotechnology Inc",
            "GenericDrug": "NULL",
            "OtherDrug": "CD19/CD20",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "Lymphoma, Non-Hodgkin's"
        },
        {
            "Company": "Shanghai Bioray Laboratory",
            "GenericDrug": "NULL",
            "OtherDrug": "CD19-UCART",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "Not Applicable",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Acute Lymphoblastic Leukemia , Non Hodgkin Lymphoma"
        },
        {
            "Company": "Shanghai Bioray Laboratory",
            "GenericDrug": "NULL",
            "OtherDrug": "BCMA-CART",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "Not Applicable",
            "PivotalIntent": "NS",
            "Target": "TNF receptor superfamily member 17",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Shanghai Unicar-Therapy Biomed",
            "GenericDrug": "NULL",
            "OtherDrug": "CD22 CAR-T Cell Therapy",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Hodgkin's/Non-Hodgkin's Lymphom"
        },
        {
            "Company": "Immune Cell Therapy",
            "GenericDrug": "NULL",
            "OtherDrug": "ICAR19 CAR-T Cells",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "NULL"
        },
        {
            "Company": "Eureka Therapeutics",
            "GenericDrug": "NULL",
            "OtherDrug": "Anti-AFP CAR-T",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "HLA-A02/AFP complex",
            "Disease": "NULL"
        },
        {
            "Company": "Guangzhou Bio-gene Technology Co., Ltd",
            "GenericDrug": "NULL",
            "OtherDrug": "BG-T19 (CD19 CAR-T)",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "B cell acute lymphoblastic leukemia/NHL  "
        },
        {
            "Company": "iCar Bio Therapeutics",
            "GenericDrug": "NULL",
            "OtherDrug": "CLL1-CD33 cCAR T cells",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD33",
            "Disease": "Acute Myeloid Leukemia"
        },
        {
            "Company": "Beijing Doing Biomedical Co.",
            "GenericDrug": "NULL",
            "OtherDrug": "CD19-CAR T cells",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Acute Lymphoblastic Leukemia"
        },
        {
            "Company": "Bellicum Pharmaceuticals",
            "GenericDrug": "NULL",
            "OtherDrug": "BPX-603",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "HER-2+ Solid Tumors"
        },
        {
            "Company": "BioAtla",
            "GenericDrug": "NULL",
            "OtherDrug": "CCT301-59",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "AXL receptor tyrosine kinase and RAR related orphan receptor A",
            "Disease": "NULL"
        },
        {
            "Company": "Shenzhen BinDeBio",
            "GenericDrug": "NULL",
            "OtherDrug": "CART-meso cells",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "Not Applicable",
            "PivotalIntent": "NS",
            "Target": "MSLN",
            "Disease": "Pancreatic Cancer"
        },
        {
            "Company": "Marino Biotechnology",
            "GenericDrug": "NULL",
            "OtherDrug": "Anti-CD19 CAR-T",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "B-cell Lymphoma"
        },
        {
            "Company": "CARsgen",
            "GenericDrug": "NULL",
            "OtherDrug": "CSG-GPC3",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "Hepatocellular carcinoma"
        },
        {
            "Company": "CARsgen",
            "GenericDrug": "NULL",
            "OtherDrug": "CSG-CD19",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Hepatocellular carcinoma"
        },
        {
            "Company": "Legend Biotech",
            "GenericDrug": "NULL",
            "OtherDrug": "JNJ-4528",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Juno Therapeutics (Part of Bristol-Myers Squibb)",
            "GenericDrug": "Lisocabtagene Maraleucel",
            "OtherDrug": "CD19-Specific CAR-T Cell Therapy",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Non-Hodgkin Lymphoma"
        },
        {
            "Company": "Juno Therapeutics (Part of Bristol-Myers Squibb)",
            "GenericDrug": "Lisocabtagene Maraleucel",
            "OtherDrug": "CD19-Specific CAR-T Cell Therapy",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "III",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Non-Hodgkin Lymphoma"
        },
        {
            "Company": "MolMed",
            "GenericDrug": "NULL",
            "OtherDrug": "CAR-CD44v6",
            "Origin": "Italy",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD44v6",
            "Disease": "Acute Myeloid Leukemia"
        },
        {
            "Company": "Celgene/Juno Therapeutics",
            "GenericDrug": "Orvacabtagene Autoleucel",
            "OtherDrug": "JCARH125",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Shenzhen BinDeBio",
            "GenericDrug": "NULL",
            "OtherDrug": "CAR-T/TCR-T cells immunotherapy",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "CNS, Glioblastoma,Esophageal,Gastric,Liver,Soft Tissue ,Sarcoma"
        },
        {
            "Company": "Autolus Limited",
            "GenericDrug": "NULL",
            "OtherDrug": "AUTO3",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Diffuse Large B Cell Lymphoma"
        },
        {
            "Company": "Bluebird Bio",
            "GenericDrug": "Idecabtagene Vicleucel",
            "OtherDrug": "Anti- BCMA CAR-T Therapy",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "United States",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "United States",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Acute Lymphocytic Leukemia"
        },
        {
            "Company": "Kite Pharma (Now Gilead Sciences)",
            "GenericDrug": "Axicabtagene ciloleucel ",
            "OtherDrug": "CD19 CAR-T Therapy",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Follicular Lymphoma"
        },
        {
            "Company": "Kite Pharma (Now Gilead Sciences)",
            "GenericDrug": "Axicabtagene ciloleucel ",
            "OtherDrug": "CD19 CAR-T Therapy",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "IV",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Non-Hodgkin's Lymphoma"
        },
        {
            "Company": "Kite Pharma (Now Gilead Sciences)",
            "GenericDrug": "Axicabtagene ciloleucel ",
            "OtherDrug": "CD19 CAR-T Therapy",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "IV",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Non-Hodgkin's Lymphoma"
        },
        {
            "Company": "Kite Pharma (Now Gilead Sciences)",
            "GenericDrug": "Axicabtagene ciloleucel ",
            "OtherDrug": "CD19 CAR-T Therapy",
            "Origin": "UK",
            "Partner": "NULL",
            "Phase": "IV",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Non-Hodgkin's Lymphoma"
        },
        {
            "Company": "Marino Biotechnology",
            "GenericDrug": "NULL",
            "OtherDrug": "Autologous Anti-CD19 4-1BB CAR T Cells",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "B-cell Lymphoma"
        },
        {
            "Company": "CARsgen",
            "GenericDrug": "NULL",
            "OtherDrug": "CSG-GPC3",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "Lung squamous cell carcinoma"
        },
        {
            "Company": "CARsgen",
            "GenericDrug": "NULL",
            "OtherDrug": "CSG-CD19",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19+",
            "Disease": "NULL"
        },
        {
            "Company": "Legend Biotech",
            "GenericDrug": "NULL",
            "OtherDrug": "JNJ-4528",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "III",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Shanghai Yake Biotechnology",
            "GenericDrug": "NULL",
            "OtherDrug": "Dual CD19/CD22 CAR-T Cells",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Acute Lymphocytic Leukemia"
        },
        {
            "Company": "Wuhan Jinyitai Biological Co.",
            "GenericDrug": "NULL",
            "OtherDrug": "CD19 CAR-T",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Acute Lymphocytic Leukemia"
        },
        {
            "Company": "Eureka Therapeutics",
            "GenericDrug": "NULL",
            "OtherDrug": "Anti-AFP CAR-T",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "Alpha Fetoprotein",
            "Disease": "Hepatocellular carcinoma"
        },
        {
            "Company": "Allife Medical Science",
            "GenericDrug": "NULL",
            "OtherDrug": "Anti-CD22 CAR NK cell therapy",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD22",
            "Disease": "B-cell Lymphoma"
        },
        {
            "Company": "Cellectis",
            "GenericDrug": "NULL",
            "OtherDrug": "C-119",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "B-cell Acute Lymphoblastic Leukemia"
        },
        {
            "Company": "Heibei Sen Lang Biotechnology",
            "GenericDrug": "NULL",
            "OtherDrug": "CD19-CAR T",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "Leukemia"
        },
        {
            "Company": "Jiangsu Alot Biotechnology Co., Ltd.",
            "GenericDrug": "NULL",
            "OtherDrug": "Nucleosome Complex CAR-T",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "Colorectal Cancer"
        },
        {
            "Company": "Hunan Zhaotai Yongren Medical Innovation Co/Guangdong Zhaotai InVivo Biomedicine Co.",
            "GenericDrug": "NULL",
            "OtherDrug": "1928zT2 T cell therapy",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Acute Leukemia"
        },
        {
            "Company": "Autolus Limited",
            "GenericDrug": "NULL",
            "OtherDrug": "AUTO2",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Bellicum Pharmaceuticals",
            "GenericDrug": "NULL",
            "OtherDrug": "BPX-601",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "PSCA",
            "Disease": "NULL"
        },
        {
            "Company": "Beijing Doing Biomedical Technology Co.",
            "GenericDrug": "NULL",
            "OtherDrug": " CD19-CAR T cells",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Acute Lymphoblastic Leukemia"
        },
        {
            "Company": "Juno Therapeutics (Part of Bristol-Myers Squibb)",
            "GenericDrug": "NULL",
            "OtherDrug": "CAR Modified T-Cells",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Leukemia"
        },
        {
            "Company": "Juno Therapeutics (Part of Bristol-Myers Squibb)",
            "GenericDrug": "NULL",
            "OtherDrug": "CD19/4-1BBL armored CAR T cell therapy",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19/4-1BBL",
            "Disease": "Chronic Lymphocytic Leukemia"
        },
        {
            "Company": "Juno Therapeutics (Part of Bristol-Myers Squibb)",
            "GenericDrug": "NULL",
            "OtherDrug": "CD19/4-1BBL armored CAR T cell therapy",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD19/4-1BBL",
            "Disease": "Acute Lymphocytic Leukemia"
        },
        {
            "Company": "Mustang Bio (Part of Fortress Biotech)",
            "GenericDrug": "NULL",
            "OtherDrug": "Autologous IL13(EQ)BBzeta/CD19t+ TCM-enriched T cells",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "NULL"
        },
        {
            "Company": "Pepromene Bio",
            "GenericDrug": "NULL",
            "OtherDrug": "BAFF-R CAR-T",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "BAFF-R",
            "Disease": "Acute Lymphocytic Leukemia"
        },
        {
            "Company": "Beijing Immunochina Medical Science & Technology",
            "GenericDrug": "NULL",
            "OtherDrug": "IM19 CAR-T",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD 19",
            "Disease": "B-cell Acute Lymphoblastic Leukemia"
        },
        {
            "Company": "Mustang Bio (Part of Fortress Biotech)",
            "GenericDrug": "NULL",
            "OtherDrug": "Anti-CD20 CAR-T cells therapy",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD20",
            "Disease": "B-cell Non-Hodgkin Lymphoma"
        },
        {
            "Company": "Juno Therapeutics (Part of Bristol-Myers Squibb)",
            "GenericDrug": "Lisocabtagene Maraleucel",
            "OtherDrug": "CD19-Specific CAR-T Cell Therapy",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Non-Hodgkin's Lymphoma"
        },
        {
            "Company": "Miltenyi Biotec",
            "GenericDrug": "NULL",
            "OtherDrug": "CD-20 CAR-T cell therapy",
            "Origin": "Germany ",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD20",
            "Disease": "Non-Hodgkin's Lymphoma"
        },
        {
            "Company": "MolMed",
            "GenericDrug": "NULL",
            "OtherDrug": "CAR-CD44v6",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "Solid Tumors"
        },
        {
            "Company": "PersonGen Biomedicine (Suzhou) Co.",
            "GenericDrug": "NULL",
            "OtherDrug": "PCAR-119",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": " I/II",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "Acute Lymphocytic Leukemia"
        },
        {
            "Company": "Juno Therapeutics (Part of Bristol-Myers Squibb)",
            "GenericDrug": "NULL",
            "OtherDrug": "JCAR-023",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "L1CAM (CD171)",
            "Disease": "Neuroblastoma"
        },
        {
            "Company": "Juno Therapeutics (Part of Bristol-Myers Squibb)",
            "GenericDrug": "Orvacabtagene Autoleucel",
            "OtherDrug": "BCMA targeting CAR T cell therapy",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Juno Therapeutics (Part of Bristol-Myers Squibb)",
            "GenericDrug": "Orvacabtagene Autoleucel",
            "OtherDrug": "BCMA targeting CAR T cell therapy",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Nanjing Bioheng Biotech",
            "GenericDrug": "NULL",
            "OtherDrug": "CTA-101",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "B-cell Acute Lymphocytic Leukemia"
        },
        {
            "Company": "Shanghai GeneChem",
            "GenericDrug": "NULL",
            "OtherDrug": "Anti-CD19 CAR-T Cells",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Systemic Lupus Erythematosus"
        },
        {
            "Company": "Beijing Doing Biomedical Co.",
            "GenericDrug": "NULL",
            "OtherDrug": "CD19-CAR T cells",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Acute Lymphoblastic Leukemia"
        },
        {
            "Company": "Sinobioway Cell Therapy",
            "GenericDrug": "NULL",
            "OtherDrug": "CD19 CAR-T",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "Not Applicable",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Lymphoma"
        },
        {
            "Company": "TNK Therapeutics",
            "GenericDrug": "NULL",
            "OtherDrug": "CAR2 Anti-CD38 A2 CAR-T Cells",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NS",
            "Target": "CD38",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Autolus Limited",
            "GenericDrug": "NULL",
            "OtherDrug": "AUTO3",
            "Origin": "UK",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "acute lymphoblastic leukaemia"
        },
        {
            "Company": "Bellicum Pharmaceuticals",
            "GenericDrug": "NULL",
            "OtherDrug": "CaspaCIDe-enabled CD19 CAR-T Cell Therapy",
            "Origin": "Italy",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Acute Lymphoblastic Leukemia"
        },
        {
            "Company": "Celgene",
            "GenericDrug": "Idecabtagene Vicleucel",
            "OtherDrug": "bb2121",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Autolus Limited",
            "GenericDrug": "NULL",
            "OtherDrug": "Auto-3",
            "Origin": "UK",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "acute lymphoblastic leukaemia"
        },
        {
            "Company": "Sensei Biotherapeutics",
            "GenericDrug": "NULL",
            "OtherDrug": "PAN-301-1",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "Human Aspartyl (Asparaginyl) beta-hydroxylase (HAAH)",
            "Disease": "Squamous Cell Carcinoma of Head and Neck Cancer"
        },
        {
            "Company": "Cellular Biomedicine Group (CBMG)",
            "GenericDrug": "NULL",
            "OtherDrug": "C-CAR011 (anti-CD19)",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "B-cell Non-Hodgkin Lymphoma"
        },
        {
            "Company": "Bluebird Bio",
            "GenericDrug": "Idecabtagene Vicleucel",
            "OtherDrug": "BB-21217",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Celyad",
            "GenericDrug": "NULL",
            "OtherDrug": "CAR-NKG2D",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NKG2D-Ligands",
            "Disease": "Acute Myeloid Leukemia"
        },
        {
            "Company": "Gilead Sciences/Kite Pharma",
            "GenericDrug": "Axicabtagene Ciloleuce",
            "OtherDrug": "KTE-C19",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Diffuse Large B-cell Lymphoma"
        },
        {
            "Company": "Celyad",
            "GenericDrug": "NULL",
            "OtherDrug": "CYAD-01",
            "Origin": "Belgium",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NKG2D-Ligands",
            "Disease": "Colon Cancer Liver Metastasis"
        },
        {
            "Company": "Tmunity Therapeutics",
            "GenericDrug": "NULL",
            "OtherDrug": "CART-PSMA-TGFßRDN cells",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "PSMA",
            "Disease": "Castrate Resistant Prostate Cancer"
        },
        {
            "Company": "Precision Biosciences",
            "GenericDrug": "NULL",
            "OtherDrug": "PBCAR269A",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NS",
            "Target": "NULL",
            "Disease": "Relapsed/Refractory Multiple Myeloma"
        },
        {
            "Company": "Tessa Theapeutics",
            "GenericDrug": "NULL",
            "OtherDrug": "HER2-CAR VST + CAdVEC",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "Head and Neck Cancer"
        },
        {
            "Company": "Eureka Therapeutics",
            "GenericDrug": "NULL",
            "OtherDrug": "Anti-AFP CAR-T",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "AFP",
            "Disease": "NULL"
        },
        {
            "Company": "Guangdong Zhaotai InVivo Biomedicine Co.",
            "GenericDrug": "NULL",
            "OtherDrug": "CD19-CAR-T2",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Acute Leukemia"
        },
        {
            "Company": "Hunan Zhaotai Yongren Medical Innovation Co/Guangdong Zhaotai InVivo Biomedicine Co.",
            "GenericDrug": "NULL",
            "OtherDrug": "GPC3- T2 targeting CAR-T ",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NS",
            "Target": "NULL",
            "Disease": "Hepatocellular carcinoma"
        },
        {
            "Company": "Autolus",
            "GenericDrug": "NULL",
            "OtherDrug": "AUTO1NG",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Paediatric Acute Lymphoblastic Leukemia"
        },
        {
            "Company": "Sinobioway Cell Therapy",
            "GenericDrug": "NULL",
            "OtherDrug": "CD19-targeted CAR-T cells",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "Not Applicable",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Leukemia"
        },
        {
            "Company": "Shanghai Unicar-Therapy Biomed",
            "GenericDrug": "NULL",
            "OtherDrug": "CAR T-cell therapy",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Acute Lymphoblastic Leukemia With Failed Remission"
        },
        {
            "Company": "Pregene",
            "GenericDrug": "NULL",
            "OtherDrug": "BCMA CAR-T",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Nanjing Legend Biotechnology Co.",
            "GenericDrug": "NULL",
            "OtherDrug": "LCAR-B4822M CAR-T cell immunotherapy",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Takeda",
            "GenericDrug": "NULL",
            "OtherDrug": "CD19 CAR-NK cell therapy",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "B-Cell Malignancies"
        },
        {
            "Company": "JW Therapeutics",
            "GenericDrug": "NULL",
            "OtherDrug": "JWCAR029",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Diffuse Large B Cell Lymphoma"
        },
        {
            "Company": "Gracell Biotechnologies",
            "GenericDrug": "NULL",
            "OtherDrug": "GC022 ",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "B-cell Acute Lymphoblastic Leukemia"
        },
        {
            "Company": "Shanghai Yake Biotechnology",
            "GenericDrug": "NULL",
            "OtherDrug": "BCMA CAR-T",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Ziopharm Oncology",
            "GenericDrug": "NULL",
            "OtherDrug": "3rd generation",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma"
        },
        {
            "Company": "Ziopharm Oncology",
            "GenericDrug": "NULL",
            "OtherDrug": "CD19 CAR-T therapy with mbIL-15",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "B-cell Lymphoma"
        },
        {
            "Company": "Cellectis",
            "GenericDrug": "NULL",
            "OtherDrug": "C-119",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Advanced Lymphoid Malignancies"
        },
        {
            "Company": "Heibei Sen Lang Biotechnology",
            "GenericDrug": "NULL",
            "OtherDrug": "CD19-CAR T",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "Leukemia"
        },
        {
            "Company": "Tianjin Mycure Medical Technology Co., Ltd",
            "GenericDrug": "NULL",
            "OtherDrug": "CD19 CAR-T",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "B-cell Acute Lymphoblastic Leukemia"
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Pancreatic  "
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "United States",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "United States",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Acute Lymphocytic Leukemia; Non-Hodgkin's Lymphoma"
        },
        {
            "Company": "Celyad",
            "GenericDrug": "NULL",
            "OtherDrug": "CAR-NKG2D",
            "Origin": "Belgium",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NKG2D-Ligands",
            "Disease": "Colon Cancer Liver Metastasis"
        },
        {
            "Company": "Kite Pharma (Now Gilead Sciences)",
            "GenericDrug": "Axicabtagene ciloleucel ",
            "OtherDrug": "CD19 CAR-T Therapy",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "B-Cell Leukemia"
        },
        {
            "Company": "Henan Hualong Biotechnology Co., Ltd",
            "GenericDrug": "NULL",
            "OtherDrug": "CD19/20 bispecific CAR-T",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "B-Cell Lymphoma Stage I"
        },
        {
            "Company": "Juno Therapeutics (Part of Bristol-Myers Squibb)",
            "GenericDrug": "NULL",
            "OtherDrug": "ET-170",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "MUC-16/IL-12",
            "Disease": "Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer"
        },
        {
            "Company": "Celgene",
            "GenericDrug": "Idecabtagene Vicleucel",
            "OtherDrug": "bb2121",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Sensei Biotherapeutics",
            "GenericDrug": "NULL",
            "OtherDrug": "PAN-301-1",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "Human Aspartyl (Asparaginyl) beta-hydroxylase (HAAH)",
            "Disease": "Head and Neck Cancer"
        },
        {
            "Company": "Sensei Biotherapeutics",
            "GenericDrug": "NULL",
            "OtherDrug": "PAN-301-1",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "Human Aspartyl (Asparaginyl) beta-hydroxylase (HAAH)",
            "Disease": "Unspecified Solid Tumor"
        },
        {
            "Company": "NantKwest",
            "GenericDrug": "NULL",
            "OtherDrug": "N-803",
            "Origin": "U.S.",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NS",
            "Target": "CD16",
            "Disease": "Lung, Non-Small CellUnspecified Solid Tumor"
        },
        {
            "Company": "Bluebird Bio",
            "GenericDrug": "Idecabtagene Vicleucel",
            "OtherDrug": "Anti- BCMA CAR-T Therapy",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "II/III",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Neoplasms"
        },
        {
            "Company": "Gilead Sciences/Kite Pharma",
            "GenericDrug": "Axicabtagene Ciloleuce",
            "OtherDrug": "KTE-C19",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "NULL"
        },
        {
            "Company": "Yake Biotechnology Ltd",
            "GenericDrug": "NULL",
            "OtherDrug": "CD19-targeted CAR-T cells",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "Not Applicable",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Leukemia, B-cell"
        },
        {
            "Company": "Helix BioPharma",
            "GenericDrug": "NULL",
            "OtherDrug": "L-DOS47",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "Non-Small Cell Lung Cancer"
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Acute Myelogenous Leukemia"
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Acute Myelogenous Leukemia"
        },
        {
            "Company": "Shenzhen BinDeBio",
            "GenericDrug": "NULL",
            "OtherDrug": "CAR-T cell immunotherapy",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "CNS, Glioblastoma, Colorectal, Esophageal, Gastric, Leukemia, Acute Lymphocytic, Leukemia, Acute Myelogenous, Leukemia, Chronic Myelogenous, Liver, Lung, Non-Small Cell, Lymphoma, Hodgkin's, Lymphoma, Non-Hodgkin's, Melanoma, Mesothelioma, Multiple Myelom"
        },
        {
            "Company": "Autolus Limited",
            "GenericDrug": "NULL",
            "OtherDrug": "AUTO1",
            "Origin": "UK",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Acute Lymphoblastic Leukemia"
        },
        {
            "Company": "Bluebird Bio",
            "GenericDrug": "Idecabtagene Vicleucel",
            "OtherDrug": "Anti- BCMA CAR-T Therapy",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Celyad",
            "GenericDrug": "NULL",
            "OtherDrug": "Allogeneic NKR-2 cell therapy",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NKG2D",
            "Disease": "Colorectal Cancer"
        },
        {
            "Company": "Shanghai Unicar-Therapy Biomed",
            "GenericDrug": "NULL",
            "OtherDrug": "CAR-T",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NS",
            "Target": "NULL",
            "Disease": "Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, CAR - T CD19/CD20/CD22/CD30"
        },
        {
            "Company": "Nanjing CART Medical Technology Co. Inc",
            "GenericDrug": "NULL",
            "OtherDrug": "CD19 CAR-T Cell Therapy",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Acute Lymphocytic Leukemia"
        },
        {
            "Company": "Bluebird Bio",
            "GenericDrug": "Idecabtagene Vicleucel",
            "OtherDrug": "Anti- BCMA CAR-T Therapy",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "United States",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Autoimmune/Inflammation: Cytokine Release Syndrome (CRS);  Acute Lymphocytic Leukemia; Non-Hodgkin's Lymphoma"
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "United States",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Chronic Lymphocytic Leukemia; Small lymphocytic lymphoma"
        },
        {
            "Company": "Kite Pharma (Now Gilead Sciences)",
            "GenericDrug": "Axicabtagene ciloleucel ",
            "OtherDrug": "CD19 CAR-T Therapy",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Large B-cell lymphoma"
        },
        {
            "Company": "Kite Pharma (Now Gilead Sciences)",
            "GenericDrug": "Axicabtagene ciloleucel ",
            "OtherDrug": "CD19 CAR-T Therapy",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Non-Hodgkin's Lymphoma"
        },
        {
            "Company": "Kite Pharma (Now Gilead Sciences)",
            "GenericDrug": "NULL",
            "OtherDrug": "KITE-585",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Milyenyi Biotec",
            "GenericDrug": "NULL",
            "OtherDrug": "CD-19 CAR-T cell therapy",
            "Origin": "Germany ",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "Y",
            "Target": "CD19",
            "Disease": "NULL"
        },
        {
            "Company": "CARsgen",
            "GenericDrug": "NULL",
            "OtherDrug": "CAR-CLD18",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Hepatocellular carcinoma"
        },
        {
            "Company": "Legend Biotech",
            "GenericDrug": "NULL",
            "OtherDrug": "JNJ-4528",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Juno Therapeutics (Part of Bristol-Myers Squibb)",
            "GenericDrug": "Lisocabtagene Maraleucel",
            "OtherDrug": "CD19-Specific CAR-T Cell Therapy",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "B-cell Lymphoma"
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "Germany ",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "NULL"
        },
        {
            "Company": "Janssen/Legend Biotech (Nanjing Legend)",
            "GenericDrug": "NULL",
            "OtherDrug": "JNJ-4528",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Fate Therapeutics",
            "GenericDrug": "NULL",
            "OtherDrug": "Bi-specific CAR-T Therapy",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD16",
            "Disease": "Non-Hodgkin's Lymphoma"
        },
        {
            "Company": "Fate Therapeutics",
            "GenericDrug": "NULL",
            "OtherDrug": "FT-500",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "Receptors derived from induced pluripotent stem cell (iPSC) line",
            "Disease": "Colorectal Cancer"
        },
        {
            "Company": "Henan Hualong Biotechnology Co., Ltd",
            "GenericDrug": "NULL",
            "OtherDrug": "CD19 CAR-T",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "Leukemia, Acute LymphocyticLymphoma, Hodgkin'sLymphoma, Non-Hodgkin's"
        },
        {
            "Company": "Juno Therapeutics (Part of Bristol-Myers Squibb)",
            "GenericDrug": "Orvacabtagene Autoleucel",
            "OtherDrug": "BCMA targeting CAR T cell therapy",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Juno Therapeutics (Part of Bristol-Myers Squibb)",
            "GenericDrug": "Orvacabtagene Autoleucel",
            "OtherDrug": "BCMA targeting CAR T cell therapy",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "United States",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Acute Lymphocytic Leukemia"
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "United States",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Acute Lymphocytic Leukemia"
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "Austria; Belgium; Canada; France; Germany; Italy; Japan; Norway; Spain",
            "Partner": "NULL",
            "Phase": "III",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Acute Lymphoblastic Leukemia"
        },
        {
            "Company": "Celgene",
            "GenericDrug": "Idecabtagene Vicleucel",
            "OtherDrug": "bb2121",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "III",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "United States",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Diffuse Large B-cell Lymphoma"
        },
        {
            "Company": "Cellular Biomedicine Group (CBMG)",
            "GenericDrug": "NULL",
            "OtherDrug": "C-CAR011 (anti-CD19)",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "B-cell Non-Hodgkin Lymphoma"
        },
        {
            "Company": "Cellectis",
            "GenericDrug": "NULL",
            "OtherDrug": "C-119",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "B-cell Acute Lymphoblastic Leukemia"
        },
        {
            "Company": "Cellectis",
            "GenericDrug": "NULL",
            "OtherDrug": "C-119",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Acute Lymphocytic Leukemia"
        },
        {
            "Company": "Cellectis",
            "GenericDrug": "NULL",
            "OtherDrug": "UCART-123",
            "Origin": "UK",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD123",
            "Disease": "Acute myeloid leukaemia"
        },
        {
            "Company": "Celyad",
            "GenericDrug": "NULL",
            "OtherDrug": "CAR-NKG2D",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD123",
            "Disease": "Acute Myelogenous Leukemia"
        },
        {
            "Company": "Celyad",
            "GenericDrug": "NULL",
            "OtherDrug": "CAR-NKG2D",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NKG2D-Ligands",
            "Disease": "Acute Myelogenous Leukemia"
        },
        {
            "Company": "Gilead Sciences/Kite Pharma",
            "GenericDrug": "Axicabtagene Ciloleuce",
            "OtherDrug": "KTE-X19",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "B-precursor acute lymphoblastic leukemia"
        },
        {
            "Company": "TNK Therapeutics (A Part of Sorrento Therapeutics)",
            "GenericDrug": "NULL",
            "OtherDrug": "CD38 CAR-T Cell Therapy",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NS",
            "Target": "CD38",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Miltenyi Biotec",
            "GenericDrug": "NULL",
            "OtherDrug": "CD-20 CAR-T cell therapy",
            "Origin": "Germany ",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD20",
            "Disease": "Melanoma (Skin)"
        },
        {
            "Company": "Celgene/Juno Therapeutics",
            "GenericDrug": "Orvacabtagene Autoleucel",
            "OtherDrug": "JCARH125",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Beijing Doing Biomedical Technology Co.",
            "GenericDrug": "NULL",
            "OtherDrug": "anti-CD19 anti-CD20 Bispecific CAR redirected autologous T-cells",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "Leukemia"
        },
        {
            "Company": "Cartesian Therapeutics",
            "GenericDrug": "NULL",
            "OtherDrug": "Descartes-08",
            "Origin": "United States",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Juno Therapeutics (Part of Bristol-Myers Squibb)",
            "GenericDrug": "NULL",
            "OtherDrug": "JTCR-016",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "WT1",
            "Disease": "NULL"
        },
        {
            "Company": "Mustang Bio (Part of Fortress Biotech)",
            "GenericDrug": "NULL",
            "OtherDrug": "Anti-CD123-CAR/CD28-costimulatory retroviral vector-transduced",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD123",
            "Disease": "Acute Myeloid Leukemia"
        },
        {
            "Company": "Nanjing Bioheng Biotech",
            "GenericDrug": "NULL",
            "OtherDrug": "CTA-101",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Acute Lymphoblastic Leukemia"
        },
        {
            "Company": "BioAtla",
            "GenericDrug": "NULL",
            "OtherDrug": "CCT301-59",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "AXL Receptor Tyrosine Kinase",
            "Disease": "Stage IV Renal Cell Carcinoma"
        },
        {
            "Company": "Kite Pharma (Now Gilead Sciences)",
            "GenericDrug": "Axicabtagene ciloleucel ",
            "OtherDrug": "CD19 CAR-T Therapy",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "III",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Diffuse Large B-cell Lymphoma"
        },
        {
            "Company": "Milyenyi Biotec",
            "GenericDrug": "NULL",
            "OtherDrug": "CD-19 CAR-T cell therapy",
            "Origin": "Israel",
            "Partner": "NULL",
            "Phase": "IV",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Non-Hodgkin Lymphoma"
        },
        {
            "Company": "Milyenyi Biotec",
            "GenericDrug": "NULL",
            "OtherDrug": "CD-19 CAR-T cell therapy",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "IV",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Large B-cell lymphoma"
        },
        {
            "Company": "CARsgen",
            "GenericDrug": "NULL",
            "OtherDrug": "CSG-GPC3",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Hepatocellular carcinoma"
        },
        {
            "Company": "iCarTAB BioMed",
            "GenericDrug": "NULL",
            "OtherDrug": "CD22-CAR-T cells",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "CD22",
            "Disease": "b cell malignancy"
        },
        {
            "Company": "Legend Biotech",
            "GenericDrug": "NULL",
            "OtherDrug": "JNJ-4528",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Multiple Myeloma "
        },
        {
            "Company": "Juno Therapeutics (Part of Bristol-Myers Squibb)",
            "GenericDrug": "Lisocabtagene Maraleucel",
            "OtherDrug": "CD19-Specific CAR-T Cell Therapy",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Non-Hodgkin Lymphoma"
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "United States",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NS",
            "Target": "CD19",
            "Disease": "Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma"
        },
        {
            "Company": "Celyad",
            "GenericDrug": "NULL",
            "OtherDrug": "CYAD-01",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I/II",
            "PivotalIntent": "NULL",
            "Target": "NKG2D-Ligands",
            "Disease": "Acute Myeloid Leukemia"
        },
        {
            "Company": "Celyad",
            "GenericDrug": "NULL",
            "OtherDrug": "CYAD-02",
            "Origin": "NULL",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "NULL",
            "Disease": "Acute Myeloid Leukemia Myelodysplastic Syndrome"
        },
        {
            "Company": "Fate Therapeutics",
            "GenericDrug": "NULL",
            "OtherDrug": "FT-500",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "Receptors derived from induced pluripotent stem cell (iPSC) line",
            "Disease": "Colorectal Cancer"
        },
        {
            "Company": "Kite Pharma (Now Gilead Sciences)",
            "GenericDrug": "Axicabtagene ciloleucel ",
            "OtherDrug": "CD19 CAR-T Therapy",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "Leukemia"
        },
        {
            "Company": "Hrain Biotechnology",
            "GenericDrug": "NULL",
            "OtherDrug": "Anti-CD19/BCMA bispecific CAR-T",
            "Origin": "China",
            "Partner": "NULL",
            "Phase": "I",
            "PivotalIntent": "NULL",
            "Target": "CD19",
            "Disease": "NULL"
        },
        {
            "Company": "Juno Therapeutics (Part of Bristol-Myers Squibb)",
            "GenericDrug": "Orvacabtagene Autoleucel",
            "OtherDrug": "BCMA targeting CAR T cell therapy",
            "Origin": "USA",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "NULL",
            "Target": "BCMA",
            "Disease": "Chronic Lymphocytic Leukemia"
        },
        {
            "Company": "Novartis",
            "GenericDrug": "tisagenlecleucel",
            "OtherDrug": "CART19",
            "Origin": "Australia; Austria; Belgium; Canada; France; Germany; Italy; Japan; Norway; Spain; United States",
            "Partner": "NULL",
            "Phase": "II",
            "PivotalIntent": "Y",
            "Target": "CD19",
            "Disease": "Cytokine Release Syndrome (CRS); Acute Lymphocytic Leukemia"
        }
    ]
}
